구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Dupixent (dupilumab) | Ebglyss (lebrikizumab-lbkz) |
Overview Company | Sanofi / Regeneron | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | IL-13 |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Moderate-to-severe atopic dermatitis |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | unique disposition of simvastatin rather than enzyme or transporter inhibition |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Concurrent IL-4 signaling and non-Type 2 dermatitis. |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Lebrikizumab binds IL-13 with high affinity, blocking IL-13Rα1/IL-4Rα signaling and downstream Type 2 inflammation in skin (barrier dysfunction, pruritus, eosinophilia). |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | EASI, IGA 0/1, pruritus NRS. |
PK/PD Half-life | ~14 days (300 mg q2w) | 24.5 h |
PK/PD Species | Mouse, EASI-75, peak pruritus NRS reduction | NHP |
PK/PD Animal (cat.) | Mouse | NHP |
PK/PD Experiment | PD | pd |
Toxicology Species | Mouse | Cynomolgus monkey, NHP |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. |
Clinical Selected reported efficacy | — | 1% |
Clinical Result source | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT03689855 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02912468 | NCT03689855 |
Preclinical Animal (cat.) | — | Mouse |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Dupixent (dupilumab) | Ebglyss (lebrikizumab-lbkz) |
Overview Company | Sanofi / Regeneron | Eli Lilly |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | IL-13 |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Moderate-to-severe atopic dermatitis |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | unique disposition of simvastatin rather than enzyme or transporter inhibition |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Concurrent IL-4 signaling and non-Type 2 dermatitis. |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Lebrikizumab binds IL-13 with high affinity, blocking IL-13Rα1/IL-4Rα signaling and downstream Type 2 inflammation in skin (barrier dysfunction, pruritus, eosinophilia). |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | EASI, IGA 0/1, pruritus NRS. |
PK/PD Half-life | ~14 days (300 mg q2w) | 24.5 h |
PK/PD Species | Mouse, EASI-75, peak pruritus NRS reduction | NHP |
PK/PD Animal (cat.) | Mouse | NHP |
PK/PD Experiment | PD | pd |
Toxicology Species | Mouse | Cynomolgus monkey, NHP |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. |
Clinical Selected reported efficacy | — | 1% |
Clinical Result source | ClinicalTrials.gov NCT02912468 | ClinicalTrials.gov NCT03689855 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02912468 | NCT03689855 |
Preclinical Animal (cat.) | — | Mouse |
추천 비교
추천 비교